Dive Brief: Novartis AG’s investigational eye drug bested Regeneron Pharmaceutical Inc.’s Eylea on additional secondary endpoints of two late-stage studies, bolstering the treatment’s potential to go head to head with Regeneron’s market leader. In HAWK trial, 35% fewer patients had intra-retinal fluid (IRF) and/or sub-retinal fluid (SRF) after 16 weeks of taking Novartis’ brolucizumab 6 mg versus […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2017-12-26 16:04:462017-12-26 16:04:46Novartis’ eye drug clearly works, but edging out Eylea won’t be easy – Dr. Pravin U. Dugel
MEETING NEWS American Academy of Ophthalmology Meeting NEW ORLEANS — Novartis’ first-in-kind molecule brolucizumab achieved clinically relevant anatomic and visual acuity gains in patients with age-related macular degeneration with every-12-week dosing, according to a speaker. Two dosages of the single-chain antibody fragment VEGF inhibitor were compared with Eylea (aflibercept, Regeneron) in two phase 3 trials, […]
Retinal Consultants of Arizona and the Retina Research Institute is dedicated to providing the most advanced, personalized patient care in Arizona. Our practice is at the forefront of implementing the latest technologies available for the diagnosis, management and treatment of retina and vitreous disease and conditions – all designed for the highest quality patient care […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2017-12-11 17:58:062017-12-11 17:58:06Dr. Derek Kunimoto First in Arizona to Use B&L’s New Bi-Blade Cutter, Vitrectomy Procedure
Phoenix – December 8th, 2017 – On Monday, November 13th during the Society Presidents’ Recognition and Awards Session held in conjunction with AAO 2017 in New Orleans, Dr. Derek Y. Kunimoto was recognized for completing his participation in the Academy’s Leadership Development Program XIXI, Class of 2017. Dr. Kunimoto was among a select group of […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2017-12-08 16:11:122021-03-25 04:37:58RCA’s Dr. Derek Y. Kunimoto Graduates From AAO Leadership Development Program
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness Brolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-inferiority vs aflibercept Significantly […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2017-11-11 15:53:502017-11-11 15:53:50Dr. Pravin Dugel: “Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness”
Phoenix – October 15th, 2017 – Spectra Eye Institute – a leading, private outpatient surgical center dedicated to comprehensive ophthalmic surgical care – has opened its North Phoenix location inside the new Retinal Consultants of Arizona North Phoenix facility at Greenway and the I-17. The new 9,200 square foot surgical facility is set up for […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2017-10-15 20:53:382021-03-25 02:16:39Spectra Eye Institute Opens Second Location at Retinal Consultants of Arizona – North Phoenix
Graybug Vision Initiates Phase 1/2 Trial of GB-102 for Wet Age-related Macular Degeneration – Novel Injectable Formulation for Potential Twice Per Year Treatment – Redwood City, CA – September 19, 2017 – Graybug Vision, Inc., a clinical-stage, venture-held pharmaceutical company committed to developing potentially transformative therapies for vision-threatening diseases including wet (neovascular) age-related macular degeneration […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2017-09-22 13:49:542017-09-22 13:49:54Retinal Research Institute First to Enroll, and the First Site in the World to Administer New Injection to Patients with AMD!
When Dr. Pravin Dugel joined a small eye clinic in Phoenix in 1994, he had bigger dreams for the practice. “My inspiration was to see if I could build the best academic private practice center in the country,” said Dugel, who was 29 years old when he started his quest. He joined Retinal Consultants of Arizona […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2017-09-19 15:11:072017-09-19 15:11:07Retinal Surgeon Expands Practice While Serving Native Americans and Third-World Countries
Pravin U. Dugel, MD, Managing Partner, Retinal Consultants of Arizona; Clinical Professor, USC Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California; Physician Executive Director, Phoenix Eye Institute, Banner University Medical Center, Phoenix, Arizona describes the promising new drugs coming up the pipeline at the 17th Euretina Congress in Barcelona, Spain. These include next generation drugs […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2017-09-10 15:13:592017-09-10 15:13:59Promising Drugs in Pipeline Debut at Euretina 2017
Retinal Consultants of Arizona will offer a Diabetic Eye Disease Support Group program on November 18th. Our staff will be on hand to meet with you and answer all your questions about Diabetic Eye Disease. In the spirit of support groups, you will be able to meet others to learn from their experiences, or to […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2017-09-05 19:47:582017-09-05 19:47:58RCA Diabetes Support Group Program
Novartis’ eye drug clearly works, but edging out Eylea won’t be easy – Dr. Pravin U. Dugel
/ Uncategorized /by retinalconsultantsDive Brief: Novartis AG’s investigational eye drug bested Regeneron Pharmaceutical Inc.’s Eylea on additional secondary endpoints of two late-stage studies, bolstering the treatment’s potential to go head to head with Regeneron’s market leader. In HAWK trial, 35% fewer patients had intra-retinal fluid (IRF) and/or sub-retinal fluid (SRF) after 16 weeks of taking Novartis’ brolucizumab 6 mg versus […]
Novartis’ VEGF inhibitor demonstrates clinically relevant anatomic, visual gains – Dr. Pravin Dugel
/ Uncategorized /by retinalconsultantsMEETING NEWS American Academy of Ophthalmology Meeting NEW ORLEANS — Novartis’ first-in-kind molecule brolucizumab achieved clinically relevant anatomic and visual acuity gains in patients with age-related macular degeneration with every-12-week dosing, according to a speaker. Two dosages of the single-chain antibody fragment VEGF inhibitor were compared with Eylea (aflibercept, Regeneron) in two phase 3 trials, […]
Dr. Derek Kunimoto First in Arizona to Use B&L’s New Bi-Blade Cutter, Vitrectomy Procedure
/ Uncategorized /by retinalconsultantsRetinal Consultants of Arizona and the Retina Research Institute is dedicated to providing the most advanced, personalized patient care in Arizona. Our practice is at the forefront of implementing the latest technologies available for the diagnosis, management and treatment of retina and vitreous disease and conditions – all designed for the highest quality patient care […]
RCA’s Dr. Derek Y. Kunimoto Graduates From AAO Leadership Development Program
/ Media /by retinalconsultantsPhoenix – December 8th, 2017 – On Monday, November 13th during the Society Presidents’ Recognition and Awards Session held in conjunction with AAO 2017 in New Orleans, Dr. Derek Y. Kunimoto was recognized for completing his participation in the Academy’s Leadership Development Program XIXI, Class of 2017. Dr. Kunimoto was among a select group of […]
Dr. Pravin Dugel: “Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness”
/ Uncategorized /by retinalconsultantsNovartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness Brolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-inferiority vs aflibercept Significantly […]
Spectra Eye Institute Opens Second Location at Retinal Consultants of Arizona – North Phoenix
/ Media /by retinalconsultantsPhoenix – October 15th, 2017 – Spectra Eye Institute – a leading, private outpatient surgical center dedicated to comprehensive ophthalmic surgical care – has opened its North Phoenix location inside the new Retinal Consultants of Arizona North Phoenix facility at Greenway and the I-17. The new 9,200 square foot surgical facility is set up for […]
Retinal Research Institute First to Enroll, and the First Site in the World to Administer New Injection to Patients with AMD!
/ Uncategorized /by retinalconsultantsGraybug Vision Initiates Phase 1/2 Trial of GB-102 for Wet Age-related Macular Degeneration – Novel Injectable Formulation for Potential Twice Per Year Treatment – Redwood City, CA – September 19, 2017 – Graybug Vision, Inc., a clinical-stage, venture-held pharmaceutical company committed to developing potentially transformative therapies for vision-threatening diseases including wet (neovascular) age-related macular degeneration […]
Retinal Surgeon Expands Practice While Serving Native Americans and Third-World Countries
/ Uncategorized /by retinalconsultantsWhen Dr. Pravin Dugel joined a small eye clinic in Phoenix in 1994, he had bigger dreams for the practice. “My inspiration was to see if I could build the best academic private practice center in the country,” said Dugel, who was 29 years old when he started his quest. He joined Retinal Consultants of Arizona […]
Promising Drugs in Pipeline Debut at Euretina 2017
/ Uncategorized /by retinalconsultantsPravin U. Dugel, MD, Managing Partner, Retinal Consultants of Arizona; Clinical Professor, USC Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California; Physician Executive Director, Phoenix Eye Institute, Banner University Medical Center, Phoenix, Arizona describes the promising new drugs coming up the pipeline at the 17th Euretina Congress in Barcelona, Spain. These include next generation drugs […]
RCA Diabetes Support Group Program
/ Uncategorized /by retinalconsultantsRetinal Consultants of Arizona will offer a Diabetic Eye Disease Support Group program on November 18th. Our staff will be on hand to meet with you and answer all your questions about Diabetic Eye Disease. In the spirit of support groups, you will be able to meet others to learn from their experiences, or to […]